[Mechanization of various steps in the treatment of laboratory glassware used in tissue culture].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to V I Marchenko.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Swine blood leukocytes have first been found capable of producing interferon the antiviral activity in human cells of which is comparable to that of native human leukocyte interferon. The influence of various factors on production of porcine leukocyte interferon active in human cells were studied. Thus, when serum was substituted with MAF in the medium used for leukocyte cultivation the titer of the produced interferon increased 4--16-fold and the content of protein impurities in the preparation decreased 10-fold or more. Marked individual interferon-producing capacity of blood leukocytes from different swine and seasonal variations in the level of this capacity were established. The optimal conditions for porcine leukocyte interferon production are: the use of leukocytes in the first few hours after bleeding of the animals; leukocyte concentration in the medium 10 million cells per 1 ml; medium 199 with 10% MAF; New-castle disease virus as interferon inducer in a dose of 10--100 CPD50 per cell. Priming of leukocytes with interferon enhanced their interferon-synthesizing capacity 2--8-fold. This new source of interferon production is readily available, and interferon is useful for public health and veterinary needs.
Explore the source record for details and available documents.
The results of comparative experiments in guinea pigs sensitized with human and porcine leukocyte interferon are presented. The animals were inoculated either intracardially or intradermally with the appropriate interferon 18-24 days after a single intramuscular or a single subcutaneous interferon injection, the latter with Freund adjuvant. The results of anaphylaxy reaction and dermal reaction permit a conclusion of lower allergenicity of porcine interferon than of human one. Daily intranasal inoculation of both porcine and human interferon for 5 days did not produce sensitization of guinea pigs, and three daily intranasal inoculations for 5 days of porcine interferon to 22 human volunteers produced no untoward systemic or local reactions nor allergic reaction to intradermal inoculation of these volunteers with porcine interferon 24 hours after termination of intranasal administration. These results justify limited clinical trials of therapeutic and prophylactic effectiveness of porcine interferon in viral ARD, using the intranasal route of interferon administration.
Production of different kinds of interferon in imported media (medium 199, Eagle's medium) greatly impedes the organization of large-scale interferon production in this country. The search for national substitutes of these media is important therefore. This paper deals with a comparative study of the use of national aminopeptide and hemohydrolysate preparations for interferon production. It was shown that substitution of serum with BAF in preparations of human and swine interferon increased their activity 2- and 4-fold, respectively, and the amount of protein was reduced 10-fold. Specimens of interferons produced with the addition of AP were less effective because the amount of protein increased 4-20-fold while the antiviral activity increased insignificantly. The most effective were interferon preparations obtained with hemohydrolysate medium. Their activity being similar, the amount of protein in interferon samples increased 11/2-2-fold only. Thus, aminopeptide and hemohydrolysate can effectively substitute medium 199 for production of leukocyte human and swine interferon.
68 children aged 3-7 years, undergoing general sanative treatment in a bronchopulmonary sanatorium in the vicinity of Moscow between November 10 and December 29, 1990, were examined. During the stay of these children in the sanatorium cases of respiratory diseases, mainly of parainfluenza etiology, were registered, which was confirmed by serological laboratory studies. At this season no cases of Legionella and Mycoplasma infections were detected. The necessity of taking prophylactic measures with the use of reaferon and lysozyme in sanative groups of children in due time, starting from the first day of the formation of such group, was substantiated.
Experiments revealed parallelism between the duration of the main manifestations of the hyporeactivity phenomenon (tolerance) in interferon induction and the duration of detection of a masked infection with the inducer virus (Newcastle disease virus) in peritoneal exudate cells of tolerant mice. It was also shown that after contact of chick fibroblasts with a dose of interferon which completely inhibited replication of vesicular stomatitis virus infecting the cells this virus was found in the cells in the masked form. Persistence of a virus interferon inducer in the masked form appears to play a significant role in the mechanism of tolerance as well as creation in the interferon-treated cells of conditions for masking viruses infecting these cells.
Decreased resistance to Krebs-2 ascitic carcinoma was demonstrated in mice which were in the state of hyporesponsiveness (tolerance) to virus interferon inducer (NDV) and increased resistance of the control mice to transplantation of tolerant carcinoma cells. Manifestations of tolerance in peritoneal and carcinoma cells were shown to be identical: interferon production and reproduction of vesicular stomatitis virus were inhibited, the number of viable cells was reduced, masked infection with NDV was detected, and the activity of cell enzymes was similarly changed. It is assumed that cellular manifestations of tolerance are the cause of reduced resistance of tolerant mice to ascitic carcinoma.